Cancer Chemotherapy and Pharmacology

Search all Cancer Chemotherapy and Pharmacology articles

Volume 68, Issue 2

August 2011

32 articles in this issue

Vascular normalization: a real benefit?
Domenico Ribatti
Mini Review 03 June 2011 Pages: 275 - 278
UGT1A1*1/*28 and *1/*6 genotypes have no effects on the efficacy and toxicity of FOLFIRI in Japanese patients with advanced colorectal cancer
Yu Sunakawa
Wataru Ichikawa
Yasutsuna Sasaki
Original Article 19 October 2010 Pages: 279 - 284
Nilotinib in patients with GIST who failed imatinib and sunitinib: importance of prior surgery on drug bioavailability
Kyu-pyo Kim
Min-Hee Ryu
Yoon-Koo Kang
Original Article 19 October 2010 Pages: 285 - 291
A prospective phase II study of 2-methoxyestradiol administered in combination with bevacizumab in patients with metastatic carcinoid tumors
Matthew H. Kulke
Jennifer A. Chan
Charles S. Fuchs
Original Article 20 October 2010 Pages: 293 - 300
Meta-analysis of neutropenia or leukopenia as a prognostic factor in patients with malignant disease undergoing chemotherapy
Kohei Shitara
Keitaro Matsuo
Kei Muro
Original Article 20 October 2010 Pages: 301 - 307
Is there any impact of plasma M30 and M65 levels on progression-free survival of patients with advanced gastric cancer?
Ahmet Bilici
Bala Basak Oven Ustaalioglu
Mahmut Gumus
Original Article 22 October 2010 Pages: 309 - 316
Clinical impact of K-ras mutation in colorectal cancer patients treated with adjuvant FOLFOX
Myung Hee Chang
In Kyu Lee
Jae Ho Byun
Original Article 24 October 2010 Pages: 317 - 323
The PI-3 kinase-Akt-MDM2-survivin signaling axis in high-risk neuroblastoma: a target for PI-3 kinase inhibitor intervention
Susan K. Peirce
Harry W. Findley
Donald L. Durden
Original Article Open access 24 October 2010 Pages: 325 - 335
Second platinum therapy in patients with uterine cervical cancer previously treated with platinum chemotherapy
Maki Tanioka
Noriyuki Katsumata
Yasuhiro Fujiwara
Original Article 26 October 2010 Pages: 337 - 342
Experiment on enhancing antitumor effect of intravenous epirubicin hydrochloride by acoustic cavitation in situ combined with phospholipid-based microbubbles
Cui-Tao Lu
Ying-Zheng Zhao
Lu Zhang
Original Article 27 October 2010 Pages: 343 - 348
Anticancer effect of (E)-2-hydroxy-3′,4,5′-trimethoxystilbene on breast cancer cells by mitochondrial depolarization
Yee Soo Chae
Jong Gwang Kim
Hoyong Park
Original Article 27 October 2010 Pages: 349 - 358
Conjugation of chlorin p ₆ to histamine enhances its cellular uptake and phototoxicity in oral cancer cells
Arpana Parihar
Alok Dube
P. K. Gupta
Original Article 27 October 2010 Pages: 359 - 369
Phase I dose-escalating study of biweekly fixed-dose rate gemcitabine plus pemetrexed in patients with advanced solid tumors
Yuan Yuan
Deirdre J. Cohen
Howard S. Hochster
Original Article 27 October 2010 Pages: 371 - 378
Phase II trial of the ribonucleotide reductase inhibitor 3-aminopyridine-2-carboxaldehydethiosemicarbazone plus gemcitabine in patients with advanced biliary tract cancer
Allyson J. Ocean
Paul Christos
Maureen E. Lane
Original Article 28 October 2010 Pages: 379 - 388
The histone deacetylase inhibitor PXD101 increases the efficacy of irinotecan in in vitro and in vivo colon cancer models
Young-Soon Na
Kyung-Ah Jung
Tae Won Kim
Original Article 03 November 2010 Pages: 389 - 398
Lack of in vivo cross-resistance with 4′-thio-ara-C against drug-resistant murine P388 and L1210 leukemias
William R. Waud
Karen S. Gilbert
John A. Secrist III
Original Article 11 November 2010 Pages: 399 - 403
Antitumor agent PX-12 inhibits HIF-1α protein levels through an Nrf2/PMF-1-mediated increase in spermidine/spermine acetyl transferase
Yon Hui Kim
Amy Coon
Garth Powis
Original Article 11 November 2010 Pages: 405 - 413
A dose-escalation study of pemetrexed and docetaxel in non-small-cell lung cancer
Athanasios Kotsakis
Sophia Agelaki
Vassilis Georgoulias
Original Article 11 November 2010 Pages: 415 - 422
Clinical benefit of early phase clinical trial participation for advanced sarcoma patients
Robin L. Jones
David Olmos
Ian R. Judson
Original Article 11 November 2010 Pages: 423 - 429
The uptake of paclitaxel and docetaxel into ex vivo porcine bladder tissue from polymeric micelle formulations
Antonia Tsallas
John Jackson
Helen Burt
Original Article 11 November 2010 Pages: 431 - 444
Improved antiangiogenic and antitumour activity of the combination of the natural flavonoid fisetin and cyclophosphamide in Lewis lung carcinoma-bearing mice
Yasmine S. Touil
Johanne Seguin
Guy G. Chabot
Original Article 11 November 2010 Pages: 445 - 455
Phase 1/pharmacology study of intraperitoneal topotecan alone and with cisplatin: potential for consolidation in ovarian cancer
Eleni Andreopoulou
Thomas Chen
Franco Muggia
Original Article 11 November 2010 Pages: 457 - 463
Prediction of human pharmacokinetics and tissue distribution of apicidin, a potent histone deacetylase inhibitor, by physiologically based pharmacokinetic modeling
Beom Soo Shin
Jürgen B. Bulitta
Sun Dong Yoo
Original Article 11 November 2010 Pages: 465 - 475
Cytotoxic responses to N-(4-hydroxyphenyl)retinamide in human pancreatic cancer cells
Maria C. Messner
Myles C. Cabot
Original Article 12 November 2010 Pages: 477 - 487
Antitumor effects of (S)-HDAC42, a phenylbutyrate-derived histone deacetylase inhibitor, in multiple myeloma cells
Li-Yuan Bai
Hany A. Omar
Jing-Ru Weng
Original Article 12 November 2010 Pages: 489 - 496
The therapeutic efficacy of S-1 against orthotopically implanted human pleural mesothelioma cells in severe combined immunodeficient mice
Trung The Van
Masaki Hanibuchi
Saburo Sone
Original Article Open access 16 November 2010 Pages: 497 - 504
Phase I study of LY2181308, an antisense oligonucleotide against survivin, in patients with advanced solid tumors
M. Tanioka
H. Nokihara
T. Tamura
Original Article 16 November 2010 Pages: 505 - 511
Preclinical pharmacokinetics, metabolism, and toxicity of azurin-p28 (NSC745104) a peptide inhibitor of p53 ubiquitination
Lee Jia
Gregory S. Gorman
Craig W. Beattie
Original Article 18 November 2010 Pages: 513 - 524
Determination of 5-fluorouracil and dihydrofluorouracil levels by using a liquid chromatography–tandem mass spectrometry method for evaluation of dihydropyrimidine dehydrogenase enzyme activity
Muhittin A. Serdar
Erdim Sertoğlu
Murat Cihan
Original Article 24 November 2010 Pages: 525 - 529
Safety and pharmacokinetics of intrathecal administration of pemetrexed in rats
Jong-Mu Sun
Mi Hyun Nam
Myung-Ju Ahn
Original Article 25 November 2010 Pages: 531 - 538
PR-104 plus sorafenib in patients with advanced hepatocellular carcinoma
Ghassan K. Abou-Alfa
Stephan L. Chan
Chao-Jung Tsao
Clinical Trial Report 19 May 2011 Pages: 539 - 545
Pilot study of PD-0325901 in previously treated patients with advanced melanoma, breast cancer, and colon cancer
Peter D. Boasberg
Charles H. Redfern
Alejandro D. Ricart
Short Communication 24 April 2011 Pages: 547 - 552

Volume 68, Issue 2

Vascular normalization: a real benefit?

UGT1A11/28 and 1/6 genotypes have no effects on the efficacy and toxicity of FOLFIRI in Japanese patients with advanced colorectal cancer

Nilotinib in patients with GIST who failed imatinib and sunitinib: importance of prior surgery on drug bioavailability

A prospective phase II study of 2-methoxyestradiol administered in combination with bevacizumab in patients with metastatic carcinoid tumors

Meta-analysis of neutropenia or leukopenia as a prognostic factor in patients with malignant disease undergoing chemotherapy

Is there any impact of plasma M30 and M65 levels on progression-free survival of patients with advanced gastric cancer?

Clinical impact of K-ras mutation in colorectal cancer patients treated with adjuvant FOLFOX

The PI-3 kinase-Akt-MDM2-survivin signaling axis in high-risk neuroblastoma: a target for PI-3 kinase inhibitor intervention

Second platinum therapy in patients with uterine cervical cancer previously treated with platinum chemotherapy

Experiment on enhancing antitumor effect of intravenous epirubicin hydrochloride by acoustic cavitation in situ combined with phospholipid-based microbubbles

Anticancer effect of (E)-2-hydroxy-3′,4,5′-trimethoxystilbene on breast cancer cells by mitochondrial depolarization

Conjugation of chlorin p ₆ to histamine enhances its cellular uptake and phototoxicity in oral cancer cells

Phase I dose-escalating study of biweekly fixed-dose rate gemcitabine plus pemetrexed in patients with advanced solid tumors

Phase II trial of the ribonucleotide reductase inhibitor 3-aminopyridine-2-carboxaldehydethiosemicarbazone plus gemcitabine in patients with advanced biliary tract cancer

The histone deacetylase inhibitor PXD101 increases the efficacy of irinotecan in in vitro and in vivo colon cancer models

Lack of in vivo cross-resistance with 4′-thio-ara-C against drug-resistant murine P388 and L1210 leukemias

Antitumor agent PX-12 inhibits HIF-1α protein levels through an Nrf2/PMF-1-mediated increase in spermidine/spermine acetyl transferase

A dose-escalation study of pemetrexed and docetaxel in non-small-cell lung cancer

Clinical benefit of early phase clinical trial participation for advanced sarcoma patients

The uptake of paclitaxel and docetaxel into ex vivo porcine bladder tissue from polymeric micelle formulations

Improved antiangiogenic and antitumour activity of the combination of the natural flavonoid fisetin and cyclophosphamide in Lewis lung carcinoma-bearing mice

Phase 1/pharmacology study of intraperitoneal topotecan alone and with cisplatin: potential for consolidation in ovarian cancer

Prediction of human pharmacokinetics and tissue distribution of apicidin, a potent histone deacetylase inhibitor, by physiologically based pharmacokinetic modeling

Cytotoxic responses to N-(4-hydroxyphenyl)retinamide in human pancreatic cancer cells

Antitumor effects of (S)-HDAC42, a phenylbutyrate-derived histone deacetylase inhibitor, in multiple myeloma cells

The therapeutic efficacy of S-1 against orthotopically implanted human pleural mesothelioma cells in severe combined immunodeficient mice

Phase I study of LY2181308, an antisense oligonucleotide against survivin, in patients with advanced solid tumors

Preclinical pharmacokinetics, metabolism, and toxicity of azurin-p28 (NSC745104) a peptide inhibitor of p53 ubiquitination

Determination of 5-fluorouracil and dihydrofluorouracil levels by using a liquid chromatography–tandem mass spectrometry method for evaluation of dihydropyrimidine dehydrogenase enzyme activity

Safety and pharmacokinetics of intrathecal administration of pemetrexed in rats

PR-104 plus sorafenib in patients with advanced hepatocellular carcinoma

Pilot study of PD-0325901 in previously treated patients with advanced melanoma, breast cancer, and colon cancer

Journal navigation